Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Breast Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.
Two decades of advances in clinical oncology — lessons learned and future directions
S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
BioNTech and InstaDeep present AI advancements, including a near exascale supercomputer, BFN models for protein sequence generation, and AI deployment across immunotherapy pipeline.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent gets FDA approval for COPD, becoming the first biologic treatment for the condition in the U.S. Dupixent also received EU and China approvals for COPD. The drug is a key revenue driver for both companies, with expected sales of around $6 billion for COPD.
FDA approves Dupixent for adults with poorly controlled COPD
FDA approves Dupixent as add-on treatment for poorly controlled COPD in adults with high eosinophil counts, marking the first biologic therapy for COPD in the U.S. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation, reducing flare-ups and improving lung function and quality of life. The approval is based on Phase 3 trials BOREAS and NOTUS, showing significant reductions in exacerbations and improvements in lung health.
Related Clinical Trials:
Regeneron, Sanofi's Dupixent approved for COPD in US, China
Regeneron and Sanofi's Dupixent (dupilumab) approved in US and China for COPD treatment, targeting interleukin 4 and 13. FDA and NMPA approvals based on Phase 3 trials showing reduced exacerbations and improved quality of life.
Dupixent approved in China as the first-ever biologic medicine for patients
Dupixent (dupilumab) approved in China for uncontrolled COPD with raised blood eosinophils, offering new hope for patients on triple therapy.
Dupixent approved in the US as the first-ever biologic medicine for patients ...
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, offering potential for improved breathing and fewer exacerbations.
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Innate Pharma SA will co-host a hybrid scientific symposium on October 3, 2024, with Mount Sinai, featuring key opinion leaders in immunotherapy. The event marks Innate Pharma's 25th anniversary and highlights next-generation immunotherapy discoveries.
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
Dupixent, a drug by Sanofi and Regeneron, has received FDA approval for treating COPD, becoming the first biologic therapy for the condition. The drug targets type 2 inflammation driven by eosinophils, showing significant reductions in COPD exacerbations in Phase 3 trials. Dupixent has previously been approved for dermatitis and asthma, contributing to €10.7 billion in sales in 2023.
© Copyright 2024. All Rights Reserved by MedPath